FusionVAC22_02: DNAJB1-PRKACA fusion transcript-based peptide vaccine for fibrolamellar hepatocellular carcinoma patients
Timeframe: 2024 – 2029 Goals: Assess the potential of a FLC therapeutic vaccine to prevent disease recurrence Principal Investigators: Juliane S. Walz, MD, CCU Translational Immunology, Department of Internal Medicine Study Background and Overview: Various research efforts supported by FCF over the last 6 years have shown that immunotherapy approaches can save FLC patients’ lives. …